Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is a clinical stage biotechnology company based in South San Francisco, California. The company employs 29 people and reported $6 million in revenue. Pionyr Immunotherapeutics is dedicated to discovering and developing novel antibody therapeutics designed to alter the tumor microenvironment (TME) and strengthen the body's natural defenses against cancer. Their Myeloid Tuning™ technology focuses on manipulating the TME to promote immune-activating cells while suppressing immune-suppressing cells, enhancing the body's ability to fight cancer, especially in conjunction with checkpoint inhibitors. In addition to Myeloid Tuning™, Pionyr is actively building a pipeline of transmembrane and intracellular targets through the utilization of advanced technologies and translational assays. Their team comprises experienced professionals with expertise in immunology, immuno-oncology, target discovery, and immunotherapy development, united by a shared dedication to translating scientific advancements into tangible cancer treatment opportunities. To learn more about Pionyr Immunotherapeutics and their innovative approach to cancer treatment, visit their website at pionyrtx.com.